Lenvatinib Mesylate
Generic Details
Generic Name
Lenvatinib-mesylate
Other Names
- Lenvima
Drug Class
- Tyrosine kinase inhibitor
Chemical Formula
C25H30N4O4
Molecular Weight
426.53 g/mol
Mechanism of Action
- Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and progression
Indications
- Treatment of advanced renal cell carcinoma
- Treatment of hepatocellular carcinoma
- Treatment of thyroid cancer
Common Dosage Forms
- Capsule
Typical Dosage
- 12 mg orally once daily
Pediatric Dosage
- Safety and efficacy not established
Geriatric Dosage
- Dose adjustment may be needed based on individual patient factors
Side Effects
- Hypertension
- Fatigue
- Diarrhea
- Decreased appetite
- Weight loss
Contraindications
- Hypersensitivity to lenvatinib
- Severe hepatic impairment
Pregnancy Category
- D
Lactation Safety
- Not recommended during breastfeeding
Drug Interactions
- Strong CYP3A4 inhibitors may increase lenvatinib levels
- Strong CYP3A4 inducers may decrease lenvatinib levels
Overdose Symptoms
- Severe hypertension
- Cardiac dysfunction
- Hepatic impairment
Antidote for Overdose
- There is no specific antidote, treatment is supportive
Storage Conditions
- Store at room temperature (20-25°C)
Pharmacokinetics
- Absorption: Well absorbed orally
- Distribution: Highly bound to plasma proteins
- Metabolism: Primarily hepatic via CYP3A4
- Excretion: Mainly in feces
Precautions
- Monitor blood pressure regularly during treatment
- Monitor for signs of hepatotoxicity
Warnings
- Hypertension may occur and should be controlled prior to starting treatment
- May cause serious cardiac events